US10533048B2ActiveUtilityA1

Anti-CGRP compositions and use thereof

98
Assignee: ALDERBIO HOLDINGS LLCPriority: May 20, 2011Filed: Aug 30, 2018Granted: Jan 14, 2020
Est. expiryMay 20, 2031(~4.9 yrs left)· nominal 20-yr term from priority
Inventors:Brian R. KovacevichLeon F. Garcia-MartinezKatie Olson AndersonBenjamin H. DutzarJens J. BillgrenJohn LathamDanielle M. MitchellPatricia Dianne McneillNicole M. JansonMaria-Cristina Loomis
C07K 16/26C07K 2317/565C07K 2317/52C07K 16/18C07K 2317/76C07K 2317/567C07K 2317/55A61K 31/485A61K 49/00C07K 2317/56C07K 2317/24A61K 2039/505A61P 25/00A61K 39/3955C07K 16/28A61K 39/395A61P 35/00C12N 15/11
98
PatentIndex Score
11
Cited by
683
References
30
Claims

Abstract

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method of treating an acute or chronic condition associated with elevated CGRP in a subject in need thereof comprising administering an effective amount of a humanized anti-calcitonin gene related polypeptide (CGRP) antibody comprising a variable light (V L ) chain polypeptide comprising the complementarity-determining region (CDR) polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 57, and a variable heavy (V H ) chain polypeptide comprising the CDR polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, and a pharmaceutically acceptable excipient. 
     
     
       2. The method of  claim 1 , wherein the humanized anti-CGRP antibody comprises a V L  chain polypeptide possessing at least 90% sequence identity to SEQ ID NO: 51 and a V H  chain polypeptide possessing at least 90% sequence identity to SEQ ID NO: 53. 
     
     
       3. The method of  claim 1 , wherein the humanized anti-CGRP antibody comprises a V L  chain polypeptide of SEQ ID NO: 51 and a V H  chain polypeptide of SEQ ID NO: 53. 
     
     
       4. The method of  claim 1 , wherein the humanized anti-CGRP antibody comprises a light chain polypeptide of SEQ ID NO: 52 and heavy chain polypeptide of SEQ ID NO: 54. 
     
     
       5. The method of  claim 1 , wherein the humanized anti-CGRP antibody comprises a human IgG1 constant domain. 
     
     
       6. The method of  claim 1 , wherein the composition is intravenously administered. 
     
     
       7. The method of  claim 2 , wherein the composition is intravenously administered. 
     
     
       8. The method of  claim 3 , wherein the composition is intravenously administered. 
     
     
       9. The method of  claim 4 , wherein the composition is intravenously administered. 
     
     
       10. The method of  claim 5 , wherein the composition is suitable for intravenous administration. 
     
     
       11. The method of  claim 1 , wherein the composition is intravenously administered. 
     
     
       12. The method of  claim 2 , wherein the composition is intravenously administered. 
     
     
       13. The method of  claim 3 , wherein the composition is subcutaneously administered. 
     
     
       14. The method of  claim 4 , wherein the composition is subcutaneously administered. 
     
     
       15. The method of  claim 5 , wherein the composition is subcutaneously administered. 
     
     
       16. The method of  claim 1 , wherein the composition is an aqueous solution. 
     
     
       17. The method of  claim 2 , wherein the composition is an aqueous solution. 
     
     
       18. The method of  claim 3 , wherein the composition is an aqueous solution. 
     
     
       19. The method of  claim 4 , wherein the composition is an aqueous solution. 
     
     
       20. The method of  claim 5 , wherein the composition is an aqueous solution. 
     
     
       21. The method of  claim 1 , wherein the composition is administered with another active agent. 
     
     
       22. The method of  claim 2 , wherein the composition is administered with another active agent. 
     
     
       23. The method of  claim 3 , wherein the composition is administered with another active agent. 
     
     
       24. The method of  claim 4 , wherein the composition is administered with another active agent. 
     
     
       25. The method of  claim 5 , wherein the composition is administered with another active agent. 
     
     
       26. The method of  claim 21 , wherein the other active agent is an analgesic or anti-migraine drug. 
     
     
       27. The method of  claim 22 , wherein the other active agent is an analgesic or anti-migraine drug. 
     
     
       28. The method of  claim 23 , wherein the other active agent is an analgesic or anti-migraine drug. 
     
     
       29. The method of  claim 24 , wherein the other active agent is an analgesic or anti-migraine drug. 
     
     
       30. The method of  claim 25 , wherein the other active agent is an analgesic or anti-migraine drug.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.